INTRODUCTION
All organisms require AAA+ protein unfoldases to actively unfold selected proteins for protein quality control and to regulate the activity of specific substrates. The prokaryotic AAA+ unfoldase ClpX is particularly specialized for regulatory unfolding, tuning the proteome to respond to environmental stress and to orchestrate changes in cell state (Gottesman, 2003; Sauer et al., 2004) . ClpX unfolds substrate proteins by ATP-driven translocation of the polypeptide chain through the central pore of its hexameric assembly. In complex with the ClpP peptidase, ClpX carries out protein degradation by translocating unfolded substrates directly into the ClpP proteolytic chamber . ClpP degrades all known substrates of ClpX, although for a few substrates, unfolding-not degradation-is the biologically required event (Konieczny and Helinski, 1997; MhammediAlaoui et al., 1994) .
In the eukaryotic cytoplasm, the 26S proteasome, which retains the basic architecture of Clp family proteases as well as a related AAA+ unfoldase component, functionally replaces the Clp family proteases. The mitochondrion, however, maintains an autonomous machinery for proteome remodeling, including ClpX, that is largely conserved from its a-proteobacterial ancestor ( Figure S1 ). Mitochondrial ClpX (mtClpX) does not contribute substantially to protein quality control (Rottgers et al., 2002; van Dyck et al., 1998) , suggesting that it may act primarily to control the activities of its substrates by regulatory unfolding and degradation, similarly to its prokaryotic homologs. Mitochondrial ClpP (mtClpP) is not as widely conserved as mtClpX, and mtClpX in organisms without ClpP lacks the ClpP interaction motif ( Figure S1 ), suggesting that mtClpX may execute a protease-independent function. The specific contributions of mtClpX to mitochondrial physiology, however, are not well understood. mtClpX is required to initiate the mitochondrial unfolded protein response (Haynes et al., 2010) and has been observed to affect mitochondrial nucleoid morphology (Bogenhagen et al., 2008; Kasashima et al., 2012) , but its mechanism in these roles is unknown. The single physiological substrate identified for mtClpX, the GTPase Noa1, is degraded by mtClpXP, but how this degradation contributes to Noa1 maintenance or regulation in vivo is unclear (Al-Furoukh et al., 2014) .
To uncover the physiological functions and partners of mtClpX, we mined previously generated large-scale genetic and chemical interaction maps in S. cerevisiae (Costanzo et al., 2010; Hoppins et al., 2011; Lee et al., 2014) . We observed strong links between the yeast mtClpX gene (MCX1) and genes involved in the first steps of heme biosynthesis ( Figure 1A ), suggesting that mtClpX might act during heme biosynthesis as well.
Nearly all organisms (with a few known exceptions among parasites) require heme for viability (Ko rený et al., 2012) , and most organisms synthesize heme endogenously. Heme is an essential cofactor for many enzymes, including several members of the respiratory chain, p450 enzymes, and sterol biosynthetic enzymes, and also acts as the sensor component of multiple environmentally responsive transcription factors (Girvan and Munro, 2013; Hamza and Dailey, 2012) . In non-plant eukaryotes, the first, rate-limiting step of heme biosynthesis is carried out in the mitochondrial matrix, and its product, 5-aminolevulinic acid (ALA), is exported to the cytoplasm ( Figure 1A ). After several further biosynthetic steps, a heme precursor is reimported into the mitochondrion, where synthesis is completed (Hamza and Dailey, 2012) . Cells tightly control heme biosynthesis to meet demand; overstimulation of heme biosynthesis drains valuable central metabolites and can cause damage from reactive unliganded heme or accumulation of toxic heme precursors, whereas insufficient heme production limits the activity of the diverse proteins that require it as a cofactor (Girvan and Munro, 2013; Hamza and Dailey, 2012) . As a consequence, causative human disease alleles of every enzyme in heme , and HEM25 alleles exhibit synthetic phenotypes. 5-fold serial dilutions from cell suspensions with optical density 600 (OD 600 ) = 1 were pinned on YP (1% yeast extract, 2% peptone) + 2% agar, with 2% glucose or 3% glycerol. ALA in ''glycerol + ALA'' indicates 50 mg/ml ALA. Growth on glucose after 2 days and on glycerol after 3 days is shown. wt, wild-type. See also Figure S1 .
biosynthesis have been identified (Camaschella, 2009; Sassa, 2006) .
In this study, we discover a stimulatory function for mtClpX in heme biosynthesis. Comparison of metabolite levels in wildtype and mcx1D cell extracts indicated that MCX1 acts to promote ALA synthesis, the initial step of heme biosynthesis. Mcx1 directly activates the enzyme that performs this step, ALA synthase (ALAS, Hem1 in yeast), by accelerating binding of the cofactor pyridoxal phosphate (PLP) to apoenzyme. This activation is conserved for mammalian homologs of these enzymes and proceeds without degradation by mtClpP. mtClpX, therefore, stimulates an essential biosynthetic process through a previously unrecognized activity for AAA+ unfoldases: accelerating cofactor insertion into its protein substrate. Finally, we find that vertebrate erythropoiesis is impaired by mtClpX knockdown, commensurate with a central, conserved role for mtClpX in heme production.
RESULTS

MCX1 Promotes Heme Biosynthesis
Using S. cerevisae genetic (Costanzo et al., 2010; Hoppins et al., 2011) and chemical (Lee et al., 2014) interaction data, we searched for genes with interaction profiles similar to that of MCX1, the yeast gene encoding mtClpX (van Dyck et al., 1998) . Because S. cerevisiae (like several other fungi), lacks a ClpP homolog, yeast Mcx1 likely acts purely as a protein unfoldase, without coupled degradation of its substrates. MCX1 was strongly correlated (Costanzo et al., 2010; Hoppins et al., 2011; Lee et al., 2014) with several genes involved in the early steps in heme biosynthesis: HEM1, the gene encoding ALAS (EC 2.3.1.37) (Arrese et al., 1983) ; HEM25, encoding the putative mitochondrial glycine/ALA transporter SLC25A38 (Guernsey et al., 2009) ; and HEM2, encoding the cytosolic enzyme that catalyzes the second step in heme biosynthesis, ALA dehydratase (ALAD; EC 4.2.1.24) (Gollub et al., 1977;  Figure 1A) .
We tested the growth of MCX1, HEM1, and HEM25 mutants singly and in combination on fermentable (glucose) or mitochondrial respiration-requiring (glycerol) carbon sources ( Figure 1B) . MCX1 deletion or mutation to an ATP hydrolysis-blocked allele (mutation E206Q in the Walker B motif, mcx1 EQ ) did not impair fermentative or respiratory growth. A mutation in the essential gene HEM1 corresponding to a sideroblastic anemia allele of human ALAS (G351R in human ALAS2 [Wintrobe and Greer, 2004] , G275R in yeast HEM1) also showed normal fermentative and respiratory growth but was lethal in combination with mcx1D ( Figure 1B ). In combination with the deletion of HEM25, MCX1 deletion or mutation dramatically impaired or abrogated mitochondrial respiration ( Figure 1B ). Respiratory growth of mcx1D hem25D, and mcx1D hem1 G275R was restored by supplementation with ALA, indicating that the synthetic phenotypes of Mcx1 resulted from a deficiency at the mitochondrial first step in heme biosynthesis. These strong synthetic phenotypes suggest an important role for Mcx1 in heme biosynthesis.
To directly test the contribution of MCX1 to heme biosynthesis, we measured heme levels in logarithmically growing yeast by total porphyrin fluorescence and by 55 Fe incorporation.
Both measurements indicated a 2-and a 3-fold reduction of heme in mcx1D and mcx1 EQ yeast, respectively ( Figure 2A ; Figure S2A) . Mirroring the severity of its respiratory growth phenotype, mcx1D hem25D yeast ( Figure S2B ) exhibited a greater heme deficiency than MCX1 mutant yeast. Supplementing the growth medium with ALA rescued the poor heme production of MCX1 mutants (Figure 2A ). This rescue strongly suggests that Mcx1 promotes the first phase of heme biosynthesis: synthesis and export of ALA.
Mcx1
Stimulates ALA Synthesis, the First Step of Heme Biosynthesis To determine the specific perturbation leading to heme deficiency in cells lacking MCX1, we monitored total metabolites in extracts from wild-type and mcx1D yeast by liquid chromatography-mass spectrometry (LC-MS). Because MCX1-correlated genes function early in heme biosynthesis, we focused on metabolites directly involved in the first mitochondrial phase ( Figure 1A ). Ion intensities detected for metabolites preceding ALA synthesis (a-ketoglutarate, succinate, glycine, glyoxylate, and serine) were equivalent in wild-type and mcx1D extracts. In contrast, the ion intensity for ALA was reduced more than 80% in mcx1D extracts ( Figure 2B ). Chemical detection of ALA in extracts corroborated this reduction ( Figure 2C ). mcx1D extracts exhibited 75% reduced ALA in this assay, and mcx1 EQ extracts had an enhanced defect ($85% reduction) ( Figure 2C ). For comparison, a reduced expression allele of Hem1 (hem1-DAmP) (Schuldiner et al., 2005) caused an 80% reduction in cellular ALA. Thus, we conclude that Mcx1 activity promotes heme production at the first step of ALA synthesis.
Mcx1 Interacts Directly with the ALAS Hem1
We hypothesized that the Mcx1 unfoldase could act directly on Hem1 (the yeast ALAS) to promote ALA synthesis. ALAS is the rate-limiting enzyme for heme biosynthesis in nearly all cell types (Hamza and Dailey, 2012) and, as such, would be a likely target for a stimulatory factor in heme biosynthesis. To test for physical interaction between Mcx1 and Hem1, we affinity purified Mcx1-3xFLAG and Mcx1 EQ -3xFLAG from yeast cell extracts and probed for copurifying Hem1-3xMyc ( Figure 2D To increase ALA production by acting on Hem1, Mcx1 might increase Hem1 protein abundance or might stimulate the activity of Hem1. Multiple mechanisms for control of ALAS abundance have been characterized (Hamza and Dailey, 2012; Tian et al., 2011) . If Mcx1 is required to maintain Hem1 protein levels, decreased Hem1 would be expected in mcx1D cells. Hem1 protein abundance was equivalent in wild-type and mcx1D lysates ( Figure 2E ). In contrast, Hem1 reduction in a hem1-DAmP strain was easily detected ( Figure 2E ).
To test whether Mcx1 acts by increasing the enzymatic activity of Hem1, we purified these proteins and tested the effect of Mcx1 on the catalytic activity of Hem1. In contrast to the large reduction in ALA in mcx1D cells, Mcx1 had little effect on the rate of ALA production by Hem1 in vitro ( Figure S3 ), leading us to consider mechanisms by which Mcx1 might stimulate Hem1 activity other than a straightforward effect on V max .
Mcx1 Activates Hem1 by Stimulating Insertion of Its Cofactor
Hem1 (like all ALASs) is part of a large, evolutionarily related enzyme family that depends on the cofactor PLP for activity (the a-family of PLP-dependent enzymes) (Eliot and Kirsch, 2004) . PLP binds covalently to an active-site lysine but requires other contacts buried in the interface of the homodimeric enzyme for stable binding (Astner et al., 2005; Gong et al., 1996) . We hypothesized that Mcx1 might stimulate formation of the PLP-loaded holoenzyme. To test this idea, we prepared PLP-free Hem1 (apoHem1) and monitored enzyme activity after the addition of PLP. As reported previously (Volland and Felix, 1984) , apoHem1 regained activity slowly on its own (0.73%/min) ( Figure 3A ). Inclusion of Mcx1 accelerated apoHem1 activation by a factor of ten ( Figure 3A ). Acceleration by Mcx1 depended on ATP, as expected if Mcx1 acts by remodeling or unfolding Hem1 ( Figure 3B ). We directly measured PLP binding to apoHem1 by monitoring the formation of the fluorescent pyridoxyllysine bond. The rate of PLP binding for apoHem1 alone (1.0%/min) ( Figure 3C ) closely matched the rate of activation for apoHem1 alone ( Figure 3A ). Mcx1 stimulated PLP binding by a factor of eight (7.6%/min), and this stimulation was also dependent on ATP ( Figures 3C and 3D ). Thus, Mcx1 accelerates formation of active Hem1 by stimulating cofactor binding to the apoenzyme.
We expect that, to efficiently activate apoHem1 in mitochondria, Mcx1 would interact preferentially with apoHem1 over holoHem1. Using purified proteins, we monitored the interaction of Mcx1-3xFLAG with apo-and holoHem1 by coimmunoprecipitation. We observed more efficient interaction of purified Hem1 with ATP-locked Mcx1 (Mcx1 EQ ) than with wild-type Mcx1 (Figures 4B and 4C) , consistent with the interaction observed between Hem1 and ATP-locked Mcx1 in cell extracts. Notably, we observed a 10-fold greater amount of Mcx1-bound apoHem1 than holoHem1 ( Figures 4B and 4C ), indicating that Mcx1 has intrinsic binding specificity for the species of Hem1 that it stimulates.
Mcx1 Activates Hem1 by Acting as an Unfoldase Most activities characterized for AAA+ unfoldases involve complete or large-scale unfolding of their substrates. Because the folded context of the ALAS active site is important for PLP binding, Mcx1 is unlikely to globally unfold the enzyme to activate it. Therefore, we sought to determine whether Mcx1 acts as an unfoldase to activate Hem1 or whether it might use an alternative mechanism. To unfold their substrates, AAA+ unfoldases translocate the substrate polyptide through the hexamer pore by the ATP-powered movement of several loops within the pore (Figure 4A ; Figure S1 ) To test whether activating Hem1 requires the unfolding machinery of Mcx1, we introduced mutations into these loops at the genomic locus. The central loop (pore-1) is essential for gripping and translocating polypeptides through the pore of the hexamer; we mutated the invariant tyrosine (mcx1 Y174A ) within this highly conserved sequence, an alteration that abrogates the unfolding activity of many AAA+ unfoldases, including ClpX (Siddiqui et al., 2004) . The RKH and pore-2 loops contribute to, but are less critical for, unfolding. They are more important for substrate selection, and their sequences diverge widely across evolution (Martin et al., 2008a) (Figure S1 ). We replaced the RKH or pore-2 loops with the highly divergent E. coli sequences (mcx1 E.c.RKH or mcx1 E.c.poreÀ2 ; Figure S1 ; E. coli ClpX substrate specificity to human mtClpX (Martin et al., 2008a) . To determine the ability of these variant enzymes to activate Hem1, we monitored ALA levels within the corresponding MCX1 mutant strains. All pore loop mutants had reduced ALA, and the magnitude of reduction correlated with the importance of the pore loop to translocation ( Figure 4A ). The pore-1 mutation caused a more severe ALA deficiency than MCX1 deletion, and substitution with E. coli RKH or pore-2 loops caused a milder ALA deficiency than MCX1 deletion. mcx1 Y174A also exhibited genetic interactions similar to those of mcx1D ( Figure 1B Figure 4D ; compare to Figure 3B for stimulation by Mcx1), suggesting that nonproductive interactions of translocationblocked Mcx1 with Hem1 interfere with Hem1 spontaneous activation. These data strongly indicate that Mcx1 activates Hem1 using the central polypeptide translocating activity of ClpX homologs.
mtClpX Activation of ALAS Is Conserved in Metazoans
Sequence conservation is high between fungal and metazoan ALAS and mtClpX, suggesting that activation of ALAS by mtClpX may be conserved. We measured the effect of mouse mtClpX on PLP activation of human erythroid ALAS (ALAS2) apoenzyme in vitro. mtClpX stimulated apoALAS2 activation approximately 2.5-fold ( Figure 5A ); this activation required the presence of ATP ( Figure S4 ). mtClpX activation of ALAS, therefore, is broadly conserved among eukaryotes. Although S. cerevisisae lacks a ClpP homolog, mtClpP is present in most other eukaryotes. Because the effect of mtClpX on ALAS is activating, the presence of a mtClpP protease might oppose this action of mtClpX. Therefore, we wanted to determine whether mtClpP interferes with this activation by coupled degradation. In the presence of mtClpP, mtClpX still stimulated PLP activation of apoALAS2, but the magnitude of this stimulation was reduced ( Figure 5A ). We monitored possible apoALAS2 degradation during incubation with mtClpXP and ATP. No degradation of apoALAS2 was observed over 30 min ( Figures 5B and  5C ), although mtClpXP efficiently degraded casein (a model substrate for mtClpXP) (Kang et al., 2002) under the same conditions.
We considered whether mtClpP might suppress mtClpX activation of apoALAS2 by suppressing mtClpX ATPase activity. Prokaryotic ClpP partially suppresses the ATPase of prokaryotic ClpX (Kim et al., 2001) . If present in the mitochondrial enzymes, ATPase suppression could explain the lower stimulation of ALAS2 by mtClpX when mtClpP is present. In the presence of mtClpP, we observed an $30%-40% suppression of the mtClpX ATPase rate ( Figure 5D ). This effect is commensurate with the magnitude of suppression of ALAS2 activation and could, therefore, account for reduced activation by mtClpXP without invoking protein degradation. We did not observe strong stimulation of mtClpX ATPase (either basal or ClpP suppressed) by ALAS2 ( Figure 5D ). Stimulation of ClpX ATPase by its substrates is common but highly variable and is less apparent for substrates that are more resistant to unfolding (Burton et al., 2003; Kenniston et al., 2003) .
mtClpX Is Required for Efficient Erythropoiesis
In organisms with circulating blood cells, heme biosynthesis is massively upregulated during erythropoiesis to meet demand from hemoglobin production (Hamza and Dailey, 2012) . Defects in heme biosynthesis cause several human anemias; congenital sideroblastic anemia is caused most commonly by mutations in ALAS2, the erythroid-specific ALA synthase (Camaschella, 2009) . Because mtClpX activates ALAS, we reasoned that it would be crucial for erythropoiesis. To facilitate increased heme production during erythropoiesis, heme biosynthetic genes are transcriptionally upregulated. We examined a previously published genome-wide transcriptional dataset for human hematopoiesis (Novershtern et al., 2011) and observed that mRNA levels of CLPX, but not CLPP, were upregulated during erythropoiesis ( Figure 6A ). We also observed upregulation of Clpx during erythroid maturation in Friend mouse erythroleukemia (MEL) cells ( Figure S5A ). These data suggest that CLPX contributes to erythropoiesis. In addition, upregulation of CLPX, but not CLPP, suggests that in this cell type, increased CLPX relative to CLPP may help to avoid CLPP suppression of ALAS activation.
To examine the contribution of mtClpX to red blood cell development, we performed morpholino-mediated knockdowns in D. rerio. Zebrafish encode two homologs of mtClpX, clpxa and clpxb. Expression of both clpxa and clpxb is ubiquitous throughout the embryo ( Figure S5B ), indicating that mtClpX function is likely not restricted to developing red blood cells. clpxa mRNA was specifically reduced by two independent morpholino sequences ( Figure S5C ; Table S2 ); both morpholinos resulted in morphologically normal embryos with reduced hemoglobin staining by o-dianisidine, indicating a specific defect in red blood cell development ( Figure 6B ). Morpholinos targeting clpxb caused toxicity without specific mRNA reduction, preventing further phenotypic analysis. To quantify the anemia we observed in clpxa knockdown embyros, we performed flow cytometry of dissociated cells from embryos with GFP-marked erythroid cells; clpxa knockdown embryos from both morpholinos exhibited an $50% reduction in GFP-positive cells at 72 hr post-fertilization (hpf) ( Figure 6C ). We also observed a reduction in early erythroid precursors at 24 hpf ( Figure S5F ), which may result from reduction in non-erythroid heme production from ALAS1 (Okano et al., 2010) . ALAS1 shares very high sequence identity with the erythroid-specific ALAS2, as well as with yeast ALAS, and is likely subject to the same stimulatory activity by mtClpX. Supplementation with ALA starting at 24 hpf fully rescued clpxa knockdowninduced anemia ( Figure 6D ). ALA supplementation specifically rescued anemia in ALAS2 mutant embryos (sauternes; Brownlie et al., 1998) , but not anemia in mitochondrial iron transporter (MFRN1, SLC25A37) mutants (frascati; Shaw et al., 2006) (Figure 6E ). These results demonstrate that ALA specifically rescues defects in ALA synthesis and not defects in later steps in heme biosynthesis. Therefore, mtClpX stimulation of ALA synthesis is conserved from S. cerevisae to vertebrates and is important for efficient heme synthesis during erythropoiesis.
DISCUSSION
In this work, we used large-scale genetic interaction data coupled with metabolic analysis to uncover a broadly conserved (A) apoALAS2 activation by PLP in vitro. Recombinant human apoALAS2 (5 mM) was incubated with PLP, with mouse mtClpX (2 mM hexamer) and human mtClpP (3 mM 14-mer) as indicated, and activation between 4 and 10 min was measured by an NAD-coupled assay. p < 0.01 for acceleration of apoALAS2 activation by mtClpX, and p < 0.05 for acceleration by mtClpXP. (B and C) mtClpXP degradation test. apoALAS2 or a-casein (5 mM each) were incubated with mouse mtClpX (0.3 mM hexamer), human mtClpP (0.8 mM 14-mer), and ATP regenerating system (including 4 mM ATP, except where noted) at 30 C, and aliquots were withdrawn and quenched with SDS at indicated time points. Proteins were separated by SDS-PAGE and stained with Sypro Orange. Quantitation of degradation is shown in (B), and gel is shown in (C). (D) Mouse mtClpX (0.3 mM hexamer) ATPase activity was monitored by NADHcoupled assay, in the presence of human mtClpP (0.8 mM 14-mer) and apoALAS2 (apoA2, 10 mM) as indicated. p < 0.01 for suppression of ATPase by mtClpP, and p < 0.05 for stimulation of ATPase by apoALAS2. Error bars represent mean ± SD. See also Figure S4 .
stimulatory activity of mtClpX in the essential biological process of heme biosynthesis. Our biochemical studies revealed that mtClpX specifically activates the apoenzyme form of ALAS, the first enzyme in heme biosynthesis, by accelerating binding to the cofactor PLP. mtClpX activation of ALAS is not coupled to degradation by mtClpP, although the presence of mtClpP results in partial inhibition. Consistent with its function in heme biosynthesis, mtClpX is important during erythropoiesis, when heme is in extreme demand as a ligand for hemoglobin. mtClpX may represent a new factor to consider in the etiology and treatment of disorders of heme biosynthesis. Why might ALAS need a chaperone for PLP insertion? The free PLP cofactor is highly reactive and is maintained at a low concentration in the cell, near or below the dissociation constant for binding to many PLP-dependent enzymes (Cheung et al., 2003; Hamfelt, 1967) . The very slow dissociation rate of PLP from its covalent attachment in active sites allows complex formation under these conditions, but spontaneous holoenzyme formation is likely to be inefficient. Therefore, active mechanisms for conjugation of PLP with apoenzymes have long been postulated. For example, pyridoxal kinase can interact with some PLPdependent enzymes to shuttle newly generated PLP into the active sites of these enzymes in vitro (Cheung et al., 2003; Kim et al., 1988 ), but it is not known whether this is a general mechanism used in vivo. There is no known pyridoxal kinase activity in the mitochondrion, which suggests that a different mechanism (such as the one described here for ALAS) might be needed to facilitate PLP conjugation within this organelle. Determining whether mtClpX acts more broadly among mitochondrial PLPdependent enzymes to facilitate PLP binding, or exclusively on ALAS, will be important to our understanding of the maturation and function of this large and important class of enzymes.
The Hsp70/90 chaperone system actively promotes ligand binding for several other classes of proteins, the best studied of which is the glucocorticoid receptor (Kirschke et al., 2014; Pratt et al., 2008) . The Hsp70/90 enzymes modulate the structure of their substrates by a different mechanism than AAA+ unfoldases. Hsp70 and Hsp90 bind to partially unfolded intermediate structures, and the ATPase cycle does not appear coupled to an unfolding power stroke like that described for AAA+ unfoldases (Russell and Matouschek, 2014; Saibil, 2013) . The requirement for a AAA+ unfoldase for apoALAS activation suggests a fundamentally different mechanism for facilitating ligand insertion, which may be dictated by the structural features of the substrate. In contrast to the structurally unstable and aggregation-prone unliganded glucocorticoid receptor (Kirschke et al., 2014) , both apo-and holoALAS are well-structured dimers. This difference in the structure and folding of the substrate proteins could explain a requirement for directed unfolding by a AAA+ unfoldase rather than trapping of partially unfolded intermediates by Hsp70/90 to accelerate PLP binding.
How does mtClpX accelerate PLP binding to ALAS? Multiple residues within the folded active site of ALAS form important contacts with PLP, and studies of the prototypical a-family PLP enzyme, aspartate aminotransferase, revealed that PLP is lost upon enzyme unfolding (Astner et al., 2005; Gong et al., 1996; Wu et al., 2003) . Because mitochondrial proteins are unfolded by the mitochondrial translocation machinery during , and SLC25A38 (indicated as S25A38) throughout erythropoiesis, as indicated in a microarray dataset described in Novershtern et al. (2011) . Erythroid development stages were defined by cell-type-specific markers as follows: 1, CD34+ CD71+ GlyAÀ; 2, CD34À CD71+ GlyAÀ; 3, CD34À CD71+ GlyA+; 4, CD34À CD71low GlyA+; 5, CD34À CD71À GlyA+. import, newly imported and refolded ALAS is likely in the apo state. mtClpX is unlikely to extensively re-unfold ALAS as part of its activation mechanism, as this action would return the enzyme to a non-PLP binding form, although it is possible that the directionality or rate of mtClpX-mediated complete unfolding could promote refolding through a PLP-binding intermediate. One attractive model is that mtClpX locally unfolds or distorts the structure of ALAS to expose the buried active site and promote efficient PLP binding (Figure 7 ). The strong preference mtClpX exhibits for binding apoHem1 indicates that it must specifically recognize a structural feature or exposed motif that is specific to the apoenzyme to initiate this activity. Two distantly related AAA+ ATPases that function as dedicated activators for red-or green-type Rubisco stimulate a reverse event, a release of an inhibitory ligand (Mueller-Cajar et al., 2011; Wang and Portis, 1992) . The better characterized red-type activase has been proposed to trigger ligand release by partial unfolding of Rubisco (Mueller-Cajar et al., 2011; Wang and Portis, 1992) . Although stimulating ligand release and stimulating cofactor association are reverse biological processes, they may be mechanistically related. It will be interesting to compare the characteristics of the unfoldase-induced structural alterations in these distantly related systems. A limited-unfolding model for ALAS activation by ClpX is consistent with the lack of ALAS degradation by mtClpXP. If unfolding by mtClpX is sufficiently limited, then the substrate protein would never be translocated far enough through the mtClpXP complex to reach the proteolytic active sites within the chamber of mtClpP. Because substrates of proteasecoupled AAA+ unfoldases are often identified or validated by their degradation, such unfolding without coupled degradation may be a much more widespread activity than indicated by the repertoire of known substrates.
How does ClpX discriminate between activation and degradation? ClpX is best understood as part of the ClpXP proteolytic machine, and all previously identified substrates of ClpX are subject to degradation by ClpP. For two substrates, the tetrameric MuA transposase and the dimeric plasmid replication factor TrfA, unfolding rather than degradation is the biologically crucial event, although both substrates can be degraded by ClpXP (Konieczny and Helinski, 1997; Mhammedi-Alaoui et al., 1994) . The function of ClpX in these cases is to extract one subunit from the complex by complete unfolding, altering the conformation of the remaining protein(s); the subsequent degradation by ClpP of the unfolded subunit, therefore, is not deleterious. In the case of ALAS, where the dimer must remain intact to function, ClpX must instead activate the specific molecule upon which it exerts force. Therefore, proteolysis by ClpP must not occur; this ClpP-independent action of ClpX is what we observe.
Within the context of the cell, AAA+ unfoldases might be specified for nonproteolytic functions by sublocalization or interaction with other binding partners that is mutually exclusive with binding to their cognate protease. For example, yeast mtClpX associates tightly with the mitochondrial inner membrane (van Dyck et al., 1998) ; this association might sterically block mtClpP association in the eukaryotes that encode it as well as facilitate efficient activation of ALAS newly imported across the membrane.
Such complete biochemical uncoupling of substrate unfolding from proteolysis has not been previously observed for any protease-coupled AAA+ unfoldase, but two recently described activities of AAA+ proteases are informative for how this may be accomplished. The C. crescentus DNA polymerase clamp loader subunit (DnaX) is partially degraded by ClpXP to produce a functional isoform (Vass and Chien, 2013) . To trigger N-end rule substrate delivery to ClpAP from the E. coli adaptor protein ClpS, the ClpA translocation pore engages ClpS itself without causing ClpS degradation (Rivera-Rivera et al., 2014; Romá n-Herná ndez et al., 2011) . In these cases, local structure that is highly resistant to unfolding (in the case of DnaX and ClpS) and/or local peptide sequence that is poorly gripped by the unfoldase (DnaX) appear to release the protein from the grasp of the unfoldase, thereby attenuating or preventing degradation. Both of these types of elements also delimit the degraded region in two transcription factors that are processed by the 26S proteasome (Tian et al., 2005) . Limited unfolding and translocation of ALAS by mtClpX, such as we propose, may be dictated by similar sequence and/or structural elements within ALAS. Defining this signal will help to delineate an emerging set of rules by which the fates of AAA+ unfoldase and protease substrates are determined.
EXPERIMENTAL PROCEDURES Statistics
Error bars indicate SD, calculated from at least three biological replicates. The p values were calculated using Student's t test, unless otherwise indicated.
Yeast Strain Construction and Culture
Strains used in this study are listed in Table S1 . Yeast genes were modified at chromosomal loci using standard homologous recombination techniques. Yeast strains were grown for experimental purposes in synthetic defined medium (YNB + CSM [yeast nitrogen base plus complete supplement mixture], Sunrise Sciences) with 2% dextrose at 30 C with shaking, unless otherwise indicated.
Heme and ALA Measurement Cellular heme levels were monitored by porphyrin fluorescence and 55
Fe labeling. ALA levels in cell extracts were quantified using modified Ehrlich's reagent. ALA production by purified proteins was quantified using modified Ehrlich's reagent or by a NAD-coupled assay as indicated. See Extended Experimental Procedures for details.
Metabolic Profiling
Metabolite extracts were made by rapid vacuum filtration of yeast liquid culture, followed by incubation of the cell-laden filter in extraction solvent partial unfolding import into matrix inactive active for heme synthesis Figure 7 . Model for mtClpX Activation of ALAS ALAS is unfolded by the mitochondrial import machinery and refolds in the mitochondrial matrix. Newly folded ALAS binds PLP slowly on its own; partial unfolding by mtClpX renders the active site of ALAS more accessible to PLP, thus accelerating holoenzyme formation. Mitochondrial import machinery (light gray), ALAS (dark gray), mtClpX (purple), and PLP (green) are diagrammed.
(40% acetonitrile, 40% methanol, 20% water). Extracts were analyzed for relative metabolite levels by LC-MS. See Extended Experimental Procedures for further details.
Protein Purification and Biochemical Assays mtClpX, mtClpP, and ALAS proteins were recombinantly produced in their mature forms (lacking the mitochondrial presequence). Biochemical assays for ALAS activity and PLP reconstitution were performed at 30 C in 25 mM HEPES (pH 7.6), 5 mM MgCl 2 , and 10% glycerol with ATP regenerating system (5 mM creatine phosphate and 50 mg/ml creatine kinase, with 2 mM ATP when indicated), supplemented with 100 mM KCl (Hem1) or 130 mM KCl and 0.75 mg/ml BSA (ALAS2). 50 mM PLP was included in reconstitution experiments. Protein concentrations during PLP reconstitution were as follows: 3 mM apoHem1, 2 mM Mcx1 (hexamer), 5 mM apoALAS2, 2 mM mouse ClpX (hexamer), 3 mM human ClpP-His 6 (14-mer). For detailed procedures, see Extended Experimental Procedures.
Zebrafish Maintenance and Studies
Wild-type (AB), dino (din tt250 ) (Hammerschmidt et al., 1996) , and Tg(globin-LCR:eGFP) (Ganis et al., 2012) zebrafish (Danio rerio) were maintained, bred, and staged according to standard methods (Lawrence et al., 2003) . Zebrafish studies were conducted with the approval of the Institutional Animal Care and Use Committee at Boston Children's Hospital. Embryos were stained for hemoglobinized cells with o-dianisidine as previously described (Amigo et al., 2009) . Flow cytometry was used to quantify erythrocytes from embryos (Cooney et al., 2013) .
Morpholino-Mediated Knockdown in Zebrafish
Splice site-blocking antisense morpholino oligomers (Table S2) were injected into one-and two-cell-stage embryos. Knockdown in morphant embryos was confirmed with real-time qRT-PCR using Taqman probes (Applied Biosystems). For details of ALA complementation, see Extended Experimental Procedures.
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